The DOI matches its Crossref record; 144 of the 145 references it cites were found in a registry or an index.
Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association
Open accessAbstract
Cardio-obstetrics has emerged as an important multidisciplinary field that requires a team approach to the management of cardiovascular disease during pregnancy. Cardiac conditions during pregnancy include hypertensive disorders, hypercholesterolemia, myocardial infarction, cardiomyopathies, arrhythmias, valvular disease, thromboembolic disease, aortic disease, and cerebrovascular diseases. Cardiovascular disease is the primary cause of pregnancy-related mortality in the United States. Advancing maternal age and preexisting comorbid conditions have contributed to the increased rates of maternal mortality. Preconception counseling by the multidisciplinary cardio-obstetrics team is essential for women with preexistent cardiac conditions or history of preeclampsia. Early involvement of the cardio-obstetrics team is critical to prevent maternal morbidity and mortality during the length of the pregnancy and 1 year postpartum. A general understanding of cardiovascular disease during pregnancy should be a core knowledge area for all cardiovascular and primary care clinicians. This scientific statement provides an overview of the diagnosis and management of cardiovascular disease during pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Support from an interdisciplinary team that may include nutritionists, kinesiologists, pharmacists, and mental health specialists, in addition to obesity medicine specialists, can be particularly effective for facilitating lifestyle modification and weight loss.17,18”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More timely initiation of therapy is associated with improved cardiovascular clinical outcomes among individuals with hypertension, diabetes, and dyslipidemias.18,53”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, recent evidence suggests that counseling related to risk reduction for CKM syndrome in high-risk women should start in the prenatal period and continue until the completion of postpartum follow-up visits for the mother and baby.16–18”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the lack of CVD event reduction, lifestyle modification with behavior change, healthy dietary modification, and physical activity, resulting in weight loss of 5% to 10%, causes improvements in CKM risk factors including remission of T2D,17,18 with the CKM benefits of lifestyle modification observed across a range of populations and geographic settings.19”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“dysregulation of these changes leading to excess insulin resistance, adipose deposition, hypercoagulability, cardiac remodeling, and decreased vascular resistance,12,18 may result in APOs.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Adverse CKM risk factor levels (overweight/obesity, hypertension, hypertriglyceridemia, diabetes, CKD) during the prepregnancy period are associated with increased risk of APOs.18,29”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While waist-hip ratio provides improved characterization of metabolic and cardiovascular risk than waist circumference, challenges of complexity of measurement and lack of standardization make it less ideal for use in clinical settings.18,29–32”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Using both BMI and waist circumference provides complementary prognostic information regarding risk for future metabolic derangements, incident CVD, and mortality.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Regular assessments of lipids, glycemia, and kidney function (eg, eGFR) are recommended with increasing frequency for higher CKM stages, as the risk for progressive metabolic and kidney disease increases along the CKM spectrum.13,18–21”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Through these mechanisms, adverse SDOH lead to CKM risk factor development.16–20”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Modest weight loss of 5% to 10% among patients with overweight or obesity and diabetes is associated with improvement in glycemic measures, BP, HDL-C, and triglycerides, among others. This can result in risk reduction for incident CKM risk factors such as diabetes and hypertension.18”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Average excess weight loss is greater with RYGB (56%) than LSG (46%),2,18 with persistent differences at 10 years.4”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Bupropion/naltrexone, phentermine/topiramate, and orlistat have all shown efficacy in improving glycemia, and the latter 2, in reducing BP.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Clinical trials have indicated a lack of heterogeneity in the effects of each class of these cardioprotective glucose-lowering therapies between those who were and were not taking the other agent.17–19,21”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In patients with symptomatic PAD, semaglutide increases walking distance.18”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Treatment of obesity-related HFpEF with the GLP-1–based therapies semaglutide and tirzepatide achieves improvements in HF patient-reported health status and quality of life, functional capacity as measured by the 6-minute walk distance (6MWD), and freedom from worsening HF events, including HF hospitalizations.1,3,17,18”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“One analysis was based on the results of the EMPEROR-PRESERVED trial, in which the effect of SLGT2i on cardiovascular mortality in HFpEF was not statistically significant (HR, 0.91; 95% CI, 0.76–1.09).”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Two high-quality simulation model–based cost-effectiveness analyses evaluated the economic value of adding SGLT2i therapy to prior GDMT in adults with symptomatic HFpEF, but neither study reported subgroup analyses by diabetes status.17,18”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In a sensitivity analysis assuming a 9% cardiovascular mortality benefit, the ICER was $174 053 per QALY gained.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Prior studies performed using a US health care sector perspective and a lifetime analytic horizon noted that SGLT2i therapy was unlikely to be cost-effective for HFpEF, but that the incremental cost-effectiveness ratio was sensitive to the effect on mortality.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These analyses suggest that SGLT2i therapy is not cost-effective at current drug prices (incremental cost-effectiveness ratio ≥$120 000 per QALY gained), but these analyses pooled individuals with and without diabetes, and there may be additional cardiovascular and kidney benefits in individuals with diabetes.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Fibrosis stage best predicts adverse outcomes in MASLD.1,18”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a lower eGFR, higher UACR, and higher CKD stages are associated with VTE development and worse outcomes.16–20”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Women planning pregnancy with diabetes are at greater risk of experiencing APOs compared to women without diabetes or those who develop GDM.18”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“An effective response to obesity pharmacotherapy has historically been described as at least 5% of body weight loss after 3 months of treatment.18”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“MBS, which induces body weight loss of >20%, also improves OSA, and is associated with reductions in CV and renal events, and in cardiovascular and all-cause mortality among people with OSA.3,18”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C.-T., Fesmire, F. M., Franklin, B. A., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,797
Erbel (2014) · doi:10.1093/eurheartj/ehu281 · Cited by 4,451
Priori, S. G., Blomström-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., Elliott, P. M., Fitzsimons, D., Hatala, R., Hindricks, G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv316 · Cited by 3,893
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000031 · Cited by 2,920
Bellamy, L., Casas, J.-P., Hingorani, A. D., & Williams, D. J. (2007) · BMJ · doi:10.1136/bmj.39335.385301.be · Cited by 2,552
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Fleisher, L. A., Jneid, H. M., Mack, M. J., McLeod, C. J., O’Gara, P. T., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000503 · Cited by 2,544
WRITING GROUP MEMBERS, Hiratzka, L. F., Bakris, G. L., Beckman, J. A., Bersin, R. M., Carr, V. F., Casey, D. E., Eagle, K. A., Hermann, L. K., Isselbacher, E. M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3181d4739e · Cited by 2,346
Prognosis of Cerebral Vein and Dural Sinus Thrombosis
Ferro, J. M., Canhão, P., Stam, J., Bousser, M., & Barinagarrementería, F. (2004) · Stroke · doi:10.1161/01.str.0000117571.76197.26 · Cited by 2,309
Research works printed but not linked: 2
- Martin, JA, Hamilton, BE, Osterman, MJK, Driscoll, AK, Drake, P. Births: final data for 2017. Natl Vital Stat Rep. 2018;67:1–50.
- 10.1136/hrt.2006.095240 · DOI
Cited by
Sorted by citations
Items 301–400 of 474
Velásquez-Penagos, J. A., Muñoz-Ortiz, E., Toro-Lugo, C., Henao-Parra, D. A., Correa-Vásquez, M., Gándara, J. A., Zapata-Montoya, A. M., Holguín-Gonzalez, E., Giraldo-Ardila, N., Milena-Campo, S., et al. (2023) · Archivos de cardiolog�a de M�xico (English ed Internet) · doi:10.24875/acme.m22000410 · Cited by 1
Obstetric anesthesia considerations in pregnancy-associated myocardial infarction: a focused review
Sharpe, E. E., Rose, C. H., & Tweet, M. S. (2024) · International Journal of Obstetric Anesthesia · doi:10.1016/j.ijoa.2024.104233 · Cited by 1
Anesthesia and analgesia for the critically ill obstetric patient with cardiac disease
Rodgers, G., & Puxty, K. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22008-1.00018-x · Cited by 1
Pregnancy and valvular heart disease
Lin, C. C., & Carbajal, F. D. J. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22008-1.00017-8 · Cited by 1
Untreated ALCAPA diagnosed in gestational ultrasonography
Hoai, L. T., Thành, N. V., Thanh, N. C., Hùng, N. Đ., Duc, M. T., & Long, N. T. (2024) · Radiology Case Reports · doi:10.1016/j.radcr.2024.10.031 · Cited by 1
Effect of pregnancy on bioprosthetic structural valve degeneration
Price, J., Ruiz, K., Lim, J., Kim, Y. Y., & Buber, J. (2024) · International Journal of Cardiology Congenital Heart Disease · doi:10.1016/j.ijcchd.2024.100559 · Cited by 1
Cardio-obstetrics in the Cardiac Intensive Care Unit: An Introductory Guide
Skowronski, J. N., Christenson, E., Shapero, K. S., Hausvater, A., Gage, A., Jeyabalan, A., & Berlacher, K. L. (2025) · US Cardiology Review · doi:10.15420/usc.2024.20 · Cited by 1
The Effect of Counselor Training Programs on the Quality of Interventions in Schools
Belangi, S. P., Nizam, Z., Rahman, R., & Chai, N. (2025) · Research Psychologie Orientation et Conseil · doi:10.70177/rpoc.v2i1.1852 · Cited by 1
Selección de lo mejor del año 2020 en cardiopatías congénitas
Soriano, J. R., Soto, A. M., Gordon, B., Vilches, I. S., Prieto-Arévalo, R., Pérez, I. S., Núñez, F. R., & Peinado, Á. A. (2020) · REC CardioClinics · doi:10.1016/j.rccl.2020.10.002 · Cited by 1
Huang, S., Samuel, B. P., Cordoba, M. I., Romero, V., Chalifoux, L. A., Fermin, D. R., & Cook, S. C. (2020) · Maternal-Fetal Medicine · doi:10.1097/fm9.0000000000000083 · Cited by 1
Dios, J. Á. T., & Benítez, S. P. (2021) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2020.09.006 · Cited by 1
Velásquez-Penagos, J. A., Ospina-Pérez, A. T., Oyuela, S. M., Muñoz-Ortiz, E., Gándara-Ricardo, J. A., & Flórez, J. P. (2022) · Revista chilena de obstetricia y ginecología · doi:10.24875/rechog.m21000040 · Cited by 1
Jiang, L., Liang, W., Yan, Y., Wang, S.-P., Li, D., & Chen, D. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i13.4226 · Cited by 1
Bigelow, C. A., Campbell, A. R., Poulose, A. K., Sannes, H., Longtin, C., Lynch-Salamon, D., & Saxena, R. (2023) · JACC Case Reports · doi:10.1016/j.jaccas.2023.102197 · Cited by 1
Getting To The Heart Of America’s Maternal Mortality Crisis
Marill, M. C. (2021) · Health Affairs · doi:10.1377/hlthaff.2021.01702 · Cited by 1
Ischemic Heart Disease and Pregnancy
Volgman, A. S., Gajo, E., & Sanghani, R. M. (2022) · JACC Advances · doi:10.1016/j.jacadv.2022.100144 · Cited by 1
Self-citationMcIntosh, J. J., & Gutterman, D. D. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318656 · Cited by 1
Easter, S. R. (2023) · Wiley eBooks · doi:10.1002/9781119636540.ch16 · Cited by 1
Getting to the Heart of the Matter
Leckey, J. A., Yeo, S., & Zègre‐Hemsey, J. K. (2020) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000754
Outcomes and Procedural Considerations for Women Undergoing PCI
Balinda, I. G., Mathenge, N., & Schmidt, A. C. S. (2021) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00888-w
Cardiovascular risk assessment: just do it
Stuenkel, C. A. (2021) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001794
A Still-Ignored Cardiovascular Risk Factor—A History of Preeclampsia—Reply
Dugani, S. B., Moorthy, M. V., & Mora, S. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1961
Analysis of Heart Diseases in Pregnancy
Ragavi, S. S., Sirisha, & Parimala (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i47b33195
Cardiovascular Outcomes of Severe Maternal Morbidity: Decades in the Making
DeFilippis, E. M., & Walsh, M. N. (2022) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008727
Six in 10 US women have poor cardiovascular health before pregnancy, study finds
Tanne, J. H. (2022) · BMJ · doi:10.1136/bmj.o402
Garcia, M. C., Young, A., & Lundberg, G. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-88953-1_29
Versorgung Schwangerer mit CV-Erkrankungen: neue AHA-Leitlinie
(2020) · Aktuelle Kardiologie · doi:10.1055/a-1221-0519
Versorgung Schwangerer mit CV-Erkrankungen: neue AHA-Leitlinie
(2021) · Kardiologie up2date · doi:10.1055/a-1378-2279
Prevalence of Cardiovascular Drugs Among Pregnant Women in Sudan
Azhari, H. E. E., Hamza, S. M. A., Mohammed., R. R., Omer, H. E., Iman, A. M., Tabein, E. M., & Idris, H. M. E. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22163676
Echocardiographic changes and impact on clinical management in pregnant women with heart disease
Patel, K., McGrath, L. B., Roldan, P. C., Taunton, M., Brookfield, K., Paré, E., & Khan, A. M. (2022) · Cardiology in the Young · doi:10.1017/s1047951122001135
Myocardial infarction in pregnancy: Current topical issues in diagnostics and treatment
Vasilchenko, M. K., Moiseeva, A. Y., Алиджанова, Х. Г., & Викторович, Б. И. (2022) · Medical alphabet · doi:10.33667/2078-5631-2022-9-8-16
Hypertension in the Pregnant Teenager
Hunley, T. E., & Jones, D. P. (2022) · Springer eBooks · doi:10.1007/978-3-319-31420-4_28-2
Baltă, M. D. (2022) · Medic ro · doi:10.26416/med.149.5.2022.7121
Congenital Heart Disease During Pregnancy
Favilli, S., & Spaziani, G. (2022) · Springer eBooks · doi:10.1007/978-3-031-07598-8_12
Cardiac obstetric care in Botswana
Mwita, J. C., Goepamang, M., & Sliwa, K. S. (2022) · SA Heart · doi:10.24170/19-3-5687
Rauch, B. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad017
Cardiopulmonary bypass in pregnancy
Patlolla, S. H., & Schaff, H. V. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18918-0.00021-8
Cardiovascular Imaging During Pregnancy in Women with Congenital and Valvular Heart Disease
Planek, M. I. C., Li, S. X., Herbst, L., Sutter, J. S., Sanghani, R. M., Volgman, A. S., & Chen, S. H. (2023) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-023-09581-5
Self-citationDeFilippis, E. M., & Kittleson, M. M. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-34103-8_14
Acute Coronary Syndrome in Pregnancy
Crousillat, D. R., Park, K. E., & Wood, M. J. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-34103-8_15
Self-citationCardiac Anesthesia and Delivery Considerations in Cardiac Patients
Easter, S. R., & Taha, B. W. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-34103-8_7
Valvular Heart Disease and Pregnancy: An Update
Hurtado, V., Lecompte-Osorio, P. A., & Crousillat, D. R. (2023) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-023-01010-6
COMO CONDUZIR COM SEGURANÇA FARMACOLÓGICA DISLIPIDEMIA NA GESTAÇÃO
de Vasconcelos, A. V., Morais, E. R. D. S., Neto, J. C. G. P., da Costa, C. D. L., dos Santos, L. T., Coares, L. N. R., Dias, C. B. L. M., do Nascimento, A. C. M., de Carvalho, R. G. V., & Filho, C. A. A. D. (2023) · doi:10.22533/at.ed.5112322094
MIOCARDIOPATIA PERIPARTO UMA DOENÇA AS VEZES ESQUECIDA
da Costa, C. D. L., Lima, E. R. L., da Silva, N. K., Morais, E. R. D. S., Carneiro, J. G. P., de Vasconcelos, A. V., Neto, J. C. G. P., de Carvalho, R. G. V., & Filho, C. A. A. D. (2023) · doi:10.22533/at.ed.5112322092
COMO DEVEMOS OLHAR A VALVOPATIA ESTENOSE MITRAL NA GESTAÇÃO
de Vasconcelos, A. V., do Nascimento, A. C. M., Dias, C. B. L. M., Silva, S. D. D. C., Barbosa, V. S., da Costa, C. D. L., Lima, E. R. L., da Silva, N. K., de Carvalho, R. G. V., & Filho, C. A. A. D. (2023) · doi:10.22533/at.ed.5112322093
PRINCIPAIS ALTERAÇÕES FISIOLÓGICAS ADAPTATIVAS DURANTE A GESTAÇÃO
Morais, E. R. D. S., Carneiro, J. G. P., Coares, L. N. R., de Vasconcelos, A. V., do Nascimento, A. C. M., Dias, C. B. L. M., Lima, E. R. L., da Silva, N. K., de Carvalho, R. G. V., & Filho, C. A. A. D. (2023) · doi:10.22533/at.ed.5112322091
Rice, B. J., Mbatidde, L., Oluleye, O. W., Onwuanyi, A., & Adedinsewo, D. A. (2023) · Journal of the National Medical Association · doi:10.1016/j.jnma.2023.11.004
Peripartum Cardiac Arrest with Terminal QRS Distortion: A Case Report
Kelly, T. D., & Harrison, N. E. (2023) · Clinical Practice and Cases in Emergency Medicine · doi:10.5811/cpcem.1323
Miscellaneous Skeletal and Connective Tissue Disorders
Grange, C., & Shiels, S. A. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009070256.014
Jackson, E., Romfh, A., Sung, Y. K., & Bodmer, N. J. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009070256.007
Challenging Cardiac Disorders in Pregnancy
Hussey, H., Hussey, P. T., & Meng, M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009070256.005
Teimoori, N., Teymoori, S., & Bayazi, M. H. (2022) · doi:10.61838/kman.aftj.3.3.3
Management of Pulmonary Hypertension during Pregnancy
Matusov, Y. P., Khan, A. A., Levian, C., Ozimek, J., & Tapson, V. F. (2024) · Current Respiratory Medicine Reviews · doi:10.2174/011573398x267692231106065628
Erwachsene mit angeborenen Herzfehlern (EMAH)
Westhoff‐Bleck, M., Bauersachs, J. K., Beerbaum, P., & von Kaisenberg, C. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-44369-9_66-1
Bigeh, A., Mehta, L. S., & Lastinger, L. T. (2024) · JACC Case Reports · doi:10.1016/j.jaccas.2024.102268
Self-citationMortalité maternelle par pathologies cardiovasculaires en France 2016–2018
Bruyère, M., Morau, E., & Verspyck, É. (2024) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2024.03.008
Pulmonary Hypertension in Pregnancy
Zaidan, M., & Duarte, A. G. (2024) · Wiley eBooks · doi:10.1002/9781119820260.ch46
Anesthesia Considerations for the Critically Ill Gravida with Cardiac Disease
Deng, Y., Tripathy, S., Wofford, L. M., Mahendra, V., & Murugan, S. (2024) · Wiley eBooks · doi:10.1002/9781119820260.ch44
Erwachsene mit angeborenen Herzfehlern (EMAH)
Westhoff‐Bleck, M., Bauersachs, J. K., Beerbaum, P., & von Kaisenberg, C. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-63506-3_66
Management of the Pregnant Woman with Congenital Heart Disease
Park, A., Barbera, K., Rose, C. H., Steury, R., Downing, T. E., Ito, S., & John, A. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-07563-6_98
Pourrafsanjani, M. H., Seyed-Mohammadzad, M., & Gholizad, H. (2024) · Journal of emergency medicine, trauma & acute care · doi:10.5339/jemtac.2024.19
Anesthesia for the Parturient with Cardiovascular Disease
Bouz, J., & Cheng, P. (2024) · Springer eBooks · doi:10.1007/978-3-031-62756-9_7
Rattan, J., Richardson, M., Toluhi, A. A., Henna Budhwani, P., Shukla, V. V., Travers, C. P., Steen, J., Wingate, M. S., Tita, A., Turan, J. M., et al. (2024) · Nursing for Women s Health · doi:10.1016/j.nwh.2024.05.005
Shen, Q., Yu, L., & Zhang, H. (2024) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0399
Khaled, A. M. A. E. M., Emam, E. A. E. R., Amin, A., & Hafez, A. A. A. E. (2024) · International Journal of Advance Research in Nursing · doi:10.33545/nursing.2024.v7.i2.d.429
Cardiac Critical Care of the Cardio-Obstetric Patient
Kharawala, A., Nagraj, S., Setia, G., Reynolds, D., & Thachil, R. (2025) · Journal of Intensive Care Medicine · doi:10.1177/08850666241308207
Maternal cardiac disease in pregnancy
Jenner, B., Jenner, W. J., Chattopadhyay, R. K., & Bhagra, C. (2025) · Obstetrics Gynaecology & Reproductive Medicine · doi:10.1016/j.ogrm.2025.01.003
Pregnancy-Related Cardiovascular Diseases: A Radiological Overview
Lauriero, F., Mazza, G., Perazzolo, A., Ottoni, G., Cipriani, A., Pereira, J., Marano, R., & Natale, L. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12020043
An unexpected battle with peripartum cardiomyopathy: a case report
Tornabene, B. A., Waldron, D., Short, H., & Duca, N. S. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2472590
Sóti, Á., Nagy, G., Györi, Z., Vass, T., Hetzman, L. T., Fenyves, B. G., & Varga, C. (2025) · International Journal of Emergency Medicine · doi:10.1186/s12245-025-00843-1
Driggin, E., Bloom, J. E., Kodali, S., Purisch, S. E., & Haythe, J. H. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.103386
A rare case of peripartum cardiomyopathy: a multidisciplinary approach
Dhanya, M., Mangaiyarkarasi, R., P., B. S. K., & Tamilselvi, D. (2025) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20250886
Wali, H., Alnazzawi, H., & Anwar, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21707-4.00008-2
Losartan and Microvascular Reactivity in Women with a History of Preeclampsia
Brewster, L. M., & van Montfrans, G. A. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf056
Pfeiffer, A. F., Young, H., Zarudskaya, O. M., Doyle, N., & Rizvi, S. A. A. (2025) · Healthcare · doi:10.3390/healthcare13121361
Premkumar, A., Cassidy, A. G., Thomas, C., Montes, M., Bhardwaj, N. R., Chor, J., Johnson, C. A., & Yamada, S. D. (2025) · Pregnancy · doi:10.1002/pmf2.70044
Hypertrophic Cardiomyopathy and Pregnancy
Weldehana, A., Yeneneh, B. T., Zewde, S., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000964
Gebelikte Kardiyovasküler Hastalıklar ve Ebelik Yaklaşımları
Orhan, Y. E. (2025) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub795.c3364
Highlighting severe lipid disorders in pregnancy
Chacra, A. P. M., Saldanha, A. L. R., Margeotto, A. P. P., Gasparoto, A. L. V., & Martinez, T. L. D. R. (2025) · International Journal of Family & Community Medicine · doi:10.15406/ijfcm.2025.09.00383
Pregnancy and breastfeeding in the mother with cardiomyopathy
Coldea, B. M., Middleton, L., Aiken, C., & Bhagra, C. (2025) · JRSM Cardiovascular Disease · doi:10.1177/20480040251352901
Pregnancy and Ischemic Heart Disease: A Review of Risks and Therapeutic Approaches
Huhulea, E. N., Huang, L., Aifuwa, E., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001013
Sehgal, S., Pollard, E. M., Charles, T., Thomas, M., Vernon, M., Sharma, G. K., & Ray, C. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12080307
Self-citationAmlodipine use during pregnancy: Current status in the medical care field in Argentina
Pérez, M. P., Ghelfi, A. M., Miranda, G., Sueldo, M. D., Zilberman, J. M., Voto, L. S., Delucchi, A., Rodriguez, P., & Renna, N. F. (2025) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2025.04.003
Munoz, Y., Eguizabal, A. S., Goldman, A., Zhang, J., Iwekaogwu, I., Padron, E., Sherwin, E. B., Carabello, G., Jacques, K., Silva, G., et al. (2025) · Medical Research Archives · doi:10.18103/mra.v13i9.6904
Integration of neural network in illness of heart disease for healthcare monitoring system
Bhardwaj, U., Correa, F. S., Singh, A., Pati, A., Khanna, L., & Krishnamoorthy, R. (2025) · Multidisciplinary Science Journal · doi:10.31893/multiscience.2025ss0105
Martin, S. L., Leach, J. M., Sinkey, R. G., Boggess, K., Dugoff, L., Sibai, B. M., Hughes, B. L., Bell, J., Aagaard, K. M., Edwards, R. K., et al. (2025) · O&G Open · doi:10.1097/og9.0000000000000116
Tlegenova, Z. S., Zholdin, B., & Amanova, A. (2025) · Heart Vessels and Transplantation · doi:10.24969/hvt.2025.600
Hoffman, K. K., MITCHELL, J. A., Simkowski, J. M., Hameed, A. B., Waks, A. B., Faulkenberg, K. D., & Page, R. L., II (2025) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2025.10.012
Hotspots and Frontiers in Arrhythmias During Pregnancy: A Bibliometric Analysis
Liu, F., Tu, C., Peng, X., & Wen, Y. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s535959
Surgical implications of rheumatic heart disease in Indian females
Chandra, A., Gutti, R., Sisodia, A., Malempati, A. R., Davulury, S. S., Reddy, S. V., & Yadav, A. (2025) · Indian Journal of Thoracic and Cardiovascular Surgery · doi:10.1007/s12055-025-02068-6
Familial Hypercholesterolaemia and the Risk of Cardiovascular Events
Conchinha, A. F., Rodrigues, A., Pack, T., Cunha, S., & Santos, A. (2025) · Cureus · doi:10.7759/cureus.97656
Rishard, M., Shilpeswarage, N. K., Shilpeswarage, U. K., Shyamali, H. M., Subhani, B., Rajaratne, K., Jayawardane, I. A., Karawita, U. G., Nissanka, N. A. K. A. I., & Wijesinghe, M. S. D. (2025) · Contraception and Reproductive Medicine · doi:10.1186/s40834-025-00410-2
Johnk, L. B., Laurie, J. G., & Lai, N. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11611-7.00089-x
Additional file 1 of Worldwide variation in cardiovascular magnetic resonance practice models
Sierra-Galán, L. M., Estrada-Lopez, E. E. S., Ferrari, V. A., Raman, S. V., Ferreira, V. M., Raj, V., Joseph, E., Schulz-Menger, J., Chan, C. W. S., Chen, S. S. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26601184
Strilchuk, L. M., & Cífková, R. (2025) · Springer eBooks · doi:10.1007/978-3-031-96562-3_25
AssociationsofGestationalDiabetes,Multiparity, and Hyperlipidemia with Preeclampsia
Soomro, Q., Channa, N. A., Hunza, Rajput, Z. A., Channar, Z., & Sheikh, M. (2025) · Allied Medical Research Journal · doi:10.59564/amrj/03.04/008
Gestational Hypertriglyceridemia Management and the Utility of Multidisciplinary Care
Zlotshewer, B., Spitz, J. A., & Dastmalchi, L. N. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2025.106522
Jin, R., Tang, H. S., & Fernando, S. (2026) · Clinical Case Reports · doi:10.1002/ccr3.71821
Cardiovascular Changes in Pregnancy: Reference Ranges and Role of Maternal Characteristics
SAMARA, A. A., & Khalil, A. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-10702-2_3
Barry, E., Kim, M. J., Goldstein, S., Denoble, A. E., Chavez, P., Hsueh, C., & Tabtabai, S. (2026) · medRxiv · doi:10.64898/2026.02.05.26345711
Metadata
- Authors
- Mehta, L. S., Warnes, C. A., Bradley, E., Burton, T., Economy, K., Mehran, R., Safdar, B., Sharma, G., Wood, M., Valente, A. M., Volgman, A. S., & On behalf of the American Heart Association Council on Clinical Cardiology; Council on Arteriosclerosis, T. A. V. B. C. O. C. A. S. N. A. S. C.
- ORCID
- Venue
- Circulation
- Published
- 2020-06-09
- Volume
- 141
- Issue
- 23
- Pages
- e884-e903
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W3022591273
- Semantic Scholar
- a4f99c537a938a755723900351845a99644d8796
- Cited by
- 464
- References
- 145
- Citations by year
- 2026: 96 · 2025: 69 · 2024: 70 · 2023: 81 · 2022: 75 · 2021: 56 · 2020: 17
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Issues in Pregnancy
- Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
- Health Sciences › Medicine › Obstetrics and Gynecology › COVID-19 Impact on Reproduction
- Keywords
- cardiovascular disease in pregnancy, cardio-obstetrics, maternal mortality, hypertensive disorders of pregnancy, preeclampsia, hypercholesterolemia, myocardial infarction, cardiomyopathy, cardiac arrhythmias, valvular heart disease, thromboembolism, aortic disease, cerebrovascular disease, preconception counseling, maternal morbidity, postpartum care
- MeSH terms
- American Heart Association, Female, Humans, Postnatal Care, Pregnancy, Pregnancy Complications, Cardiovascular, United States, Delivery, Obstetric
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
